Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute

StopCraving_12

Recently Joined
Joined
Feb 25, 2025
Posts
21
Like Points
29
CIty/State
United States
"With the recent transition to the Trump administration—whose leader has repeatedly criticized pharmaceutical companies for "getting away with murder" on pricing and specifically targeted the cost of weight loss medications—I have wondered whether the FDA might reverse course under new leadership and side with compounders offering lower-priced alternatives. The FDA's new court filing indicates that the agency is standing firmly with patent holders and the drug approval system that grants market exclusivity"

patentlyo.com

Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute

by Dennis Crouch Since late 2022, the extraordinary demand for glucagon-like peptide-1 receptor agonists (GLP-1s) like Eli Lilly's tirzepatide (marketed …
patentlyo.com
 
Taking emotion out of it. It is Eli Lilly and Novo's patents for both tirzepatide and semaglutide and compound medications were never meant to be permanent. NO, I am not shilling for Lilly, just saying. I mix and match both compound, grey and brand. It all works the same. I will say Eli Lilly expanding their Cash Pay program so vials up to 10mg are now under $499 a month is a start, and more affordable for the general public.

Of course, this was a tactic to showcase availability and the medication not being in shortage.
 
jasonlovespeptides said:
Taking emotion out of it. It is Eli Lilly and Novo's patents for both tirzepatide and semaglutide and compound medications were never meant to be permanent. NO, I am not shilling for Lilly, just saying. I mix and match both compound, grey and brand. It all works the same. I will say Eli Lilly expanding their Cash Pay program so vials up to 10mg are now under $499 a month is a start, and more affordable for the general public.

Of course, this was a tactic to showcase availability and the medication not being in shortage.
Click to expand...
That’s right, they own the patents and charge usurious rates for the meds to US patients. That’s why I can’t understand why anyone thought they’d (companies or admin) would be sympathetic to US patients, esp given they’re champions of citizen united.
 
I STRONGLY support OR CONDEMN the current thing that MAY OR MAY NOT be happening, WHATEVER it is OR IS NOT, and WHOEVER IS or IS NOT responsible. Thank you, and may Gort blargh America. 🦅
 
Last edited:
exploitedworkerbee said:
I’m locking this thread the moment it gets even a little bit into partisan politics.

I give it 2 hours but prove me wrong.
Click to expand...
An article with the words "Republican administration" in the title possibly getting into partisan politics? I can't imagine what you mean.
 
They are publicly traded corporations with peoples retirements and huge funds invested into them. Obviously, they will answer to their customers: The shareholders. It’s just reality. They must be compelled to legally. Sure they may preemptively lower it but it would only be as a precaution in order to prevent forced legal coercion. That, or they believe they can make more money by selling more at a lower price.
 
I think the current administration is playing "show me the money" with the pharmaceutical companies and that is why they have shown stances on both sides of the issue. If Eli wants to keep the exclusivity and for Trump to continue the Biden plan to expand Medicaid and Medicare to cover the weight loss drugs in 2026 as planned they are going to have to cough up some dough to Trump. It's a sound theory but Trump is chaos, so it's anyone's guess.
 
Lilly expanding their cash for vials program does provide an off ramp for many that were paying for compound. It is only about $100-$200 more per month than compound if on a dose <=10mg.

Still super expensive compared to gray but for many this could be an option. With insurance my Zepbound co-pay is just over $200 (for any dose) so $500 without insurance isn't as crazy as it sounds, especially if you don't have access to, or don't want to go gray.
 
GimmeABreak said:
Lilly expanding their cash for vials program does provide an off ramp for many that were paying for compound. It is only about $100-$200 more per month than compound if on a dose <=10mg.

Still super expensive compared to gray but for many this could be an option. With insurance my Zepbound co-pay is just over $200 (for any dose) so $500 without insurance isn't as crazy as it sounds, especially if you don't have access to, or don't want to go gray.
Click to expand...
I believe the majority of Americans who want to use GLP1+ drugs will be unlikely to try grey, thinking that someone terrible is likely to happen if they use grey. As a result, I'm happy that Eli Lilly has made their prices for those without insurance less outrageous.
 
GimmeABreak said:
Lilly expanding their cash for vials program does provide an off ramp for many that were paying for compound. It is only about $100-$200 more per month than compound if on a dose <=10mg.

Still super expensive compared to gray but for many this could be an option. With insurance my Zepbound co-pay is just over $200 (for any dose) so $500 without insurance isn't as crazy as it sounds, especially if you don't have access to, or don't want to go gray.
Click to expand...
I think they released vials in the US in part to negate any compounding argument for odd dosages. Now if a patient says they can't tolerate 5mg and need 4mg it can happen. Takes the legs off one of the compounders main arguments. Some telehealth anticipated this from the beginning... I know Henry Meds initial dosage schedule didn't align with Lilly's and several telehealth offered unique dosages the moment Tirz came off the shortage list in the fall.
 
Last edited:
raw_oyster_eater said:
i don't know why a couple more weight loss drugs can't be expedited. so many in these damn trials that will take forever. maybe they can help with that.
Click to expand...
I don’t know how something can be better than what’s already here. It seems so amazing to me as is. Unless it’s a competitor of NN or EL, there is no benefit to something else coming out. The smart financial play is to wait until the patent expires.
 
raw_oyster_eater said:
there's like 30 in development/testing. lets push some of them out.
Click to expand...
With patents not expiring for many more years, competition is our best bet. If people had an option between 3 or 4 drugs from different companies that acted just like Tirz, EL wouldn't have a cornered market and wouldn't get away with highway robbery for long.

Although from what I hear, Tirz in other countries is WAYYY cheaper. The goverment could use that, I'd think, to force EL to drop the price.
 
ktg123 said:
With patents not expiring for many more years, competition is our best bet. If people had an option between 3 or 4 drugs from different companies that acted just like Tirz, EL wouldn't have a cornered market and wouldn't get away with highway robbery for long.

Although from what I hear, Tirz in other countries is WAYYY cheaper. The goverment could use that, I'd think, to force EL to drop the price.
Click to expand...
It is cheaper in most countries because the government negotiates drug prices.

In the US this is only doable for a subset of drugs under medicare. If you want this to be a thing in general, call your representative and ask for it.
 
hexagonal said:
It is cheaper in most countries because the government negotiates drug prices.

In the US this is only doable for a subset of drugs under medicare. If you want this to be a thing in general, call your representative and ask for it.
Click to expand...
Which is frustrating because all the drug companies receive government money for research.
 
You must log in or register to reply here.

Trending Topics

Latest Posts

Members Online

Total: 171 (10 Members & 161 Guests)

Forum Statistics

Threads
3,358
Posts
55,166
Members
7,445
Latest member
Rimla

Share This Page!

Top Bottom